Income Statement Theraclion OTC Markets
Stocks
TCLIF
FR0010120402
Advanced Medical Equipment & Technology
|
Market Closed -
OTC Markets
14:47:35 2026-04-08 EDT
|
5-day change | 1st Jan Change | ||
| 0.5320 USD | +66.25% |
|
-.--% | +66.25% |
| 07-23 | Theraclion SA Reports Consolidated Revenue Results for the First Half Ended June 30, 2026 | CI |
| 07-09 | Theraclion Announces Board Changes | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.48M | 1.24M | 1.82M | 830K | 652K | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | 1.48M | 1.24M | 1.82M | 830K | 652K | |||||
Cost of Goods Sold, Total | 2.88M | 4.29M | 2.9M | 4.66M | 3.72M | |||||
Gross Profit | -1.4M | -3.05M | -1.08M | -3.83M | -3.07M | |||||
Selling General & Admin Expenses, Total | 3.14M | 3.1M | 3.15M | 3.36M | 3.67M | |||||
Depreciation & Amortization - (IS) | 131K | 182K | 205K | 396K | 399K | |||||
Other Operating Expenses | -136K | -26.96K | -1.29M | -760K | 605K | |||||
Other Operating Expenses, Total | 3.14M | 3.26M | 2.07M | 2.99M | 4.68M | |||||
Operating Income | -4.53M | -6.31M | -3.15M | -6.82M | -7.75M | |||||
Interest Expense, Total | -74.06K | -44.06K | -31.46K | -21.54K | -162K | |||||
Interest And Investment Income | - | - | 30.78K | 7.03K | 19K | |||||
Net Interest Expenses | -74.06K | -44.06K | -670 | -14.5K | -143K | |||||
Currency Exchange Gains (Loss) | -83.01K | 67.97K | -33.07K | - | - | |||||
Other Non Operating Income (Expenses) | -81.76K | -22.57K | -1.89M | 61.36K | 1K | |||||
EBT, Excl. Unusual Items | -4.77M | -6.31M | -5.08M | -6.77M | -7.89M | |||||
Gain (Loss) On Sale Of Investments | 103K | -9.77K | -29.66K | 1.85K | -7K | |||||
Gain (Loss) On Sale Of Assets | -2.03K | - | - | 300 | 1K | |||||
Asset Writedown | - | - | - | - | 1.37M | |||||
Other Unusual Items | 30.07K | 350K | 384K | 29.27K | - | |||||
EBT, Incl. Unusual Items | -4.64M | -5.97M | -4.72M | -6.74M | -6.53M | |||||
Income Tax Expense | -883K | -1M | -1.05M | -984K | -837K | |||||
Earnings From Continuing Operations | -3.76M | -4.96M | -3.68M | -5.76M | -5.69M | |||||
Net Income to Company | -3.76M | -4.96M | -3.68M | -5.76M | -5.69M | |||||
Net Income - (IS) | -3.76M | -4.96M | -3.68M | -5.76M | -5.69M | |||||
Net Income to Common Incl Extra Items | -3.76M | -4.96M | -3.68M | -5.76M | -5.69M | |||||
Net Income to Common Excl. Extra Items | -3.76M | -4.96M | -3.68M | -5.76M | -5.69M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.17 | -0.17 | -0.08 | -0.12 | -0.1 | |||||
Basic EPS - Continuing Operations | -0.17 | -0.17 | -0.08 | -0.12 | -0.1 | |||||
Basic Weighted Average Shares Outstanding | 22.77M | 29.39M | 48.28M | 46.26M | 59.8M | |||||
Net EPS - Diluted | -0.17 | -0.17 | -0.08 | -0.12 | -0.1 | |||||
Diluted EPS - Continuing Operations | -0.17 | -0.17 | -0.08 | -0.12 | -0.1 | |||||
Diluted Weighted Average Shares Outstanding | 22.77M | 29.39M | 48.28M | 46.26M | 59.8M | |||||
Normalized Basic EPS | -0.13 | -0.13 | -0.07 | -0.09 | -0.08 | |||||
Normalized Diluted EPS | -0.13 | -0.13 | -0.07 | -0.09 | -0.08 | |||||
Supplemental Items | ||||||||||
EBITDA | -4.4M | -6.16M | -3.02M | -6.5M | -7.35M | |||||
EBITA | -4.44M | -6.21M | -3.05M | -6.71M | -7.75M | |||||
EBIT | -4.53M | -6.31M | -3.15M | -6.82M | -7.75M | |||||
Total Revenues (As Reported) | 1.71M | 1.37M | 3.92M | 2.16M | 2.32M | |||||
Effective Tax Rate - (Ratio) | 19.01 | 16.79 | 22.21 | 14.59 | 12.82 | |||||
Total Current Taxes | - | - | - | - | - | |||||
Normalized Net Income | -2.98M | -3.94M | -3.17M | -4.23M | -4.93M | |||||
Non-Cash Pension Expense | - | - | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 3.82M | 4.3M | 3.9M | - | 2M |
- Stock Market
- Stocks
- ALTHE Stock
- TCLIF Stock
- Financials Theraclion
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















